Dose-reduced Versus Standard Conditioning in MDS/sAML (RICMAC)

European Society for Blood and Marrow Transplantation

Status and phase

Terminated

Phase 3

Conditions

Secondary Acute Myeloid Leukemia

Myelodysplastic Syndromes

Treatments

Other: Reduced Intensity Conditioning

Other: Myeloablative conditioning

Study type

Interventional

Funder types

NETWORK

Industry

Identifiers

NCT01203228

2005-002011-24

EBMT 42205525

Details and patient eligibility

About

In this trial dose reduced conditioning is compared to standard conditioning followed by allogeneic stem cell transplantation from related or unrelated donors in patients with MDS or secondary AML.

Conditioning is the very high dose chemotherapy treatment that is given in the days before the stem cell transplant.

The hypothesis is that a dose reduced conditioning will reduce the non-relapse mortality from 40% to 20% at one year after allogeneic stem cell transplantation.

Enrollment

129 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Disease: Cytologically proven primary or therapy-related myelodysplastic syndrome (MDS), either as
- refractory anaemia (RA) according FAB or RA with or without dysplasia according WHO,
- refractory anaemia with ringsideroblasts (RARS) according FAB or RARS with or without dysplasia according WHO,
- refractory anaemia with excess of blasts (RAEB) according FAB or RAEB I or RAEB II according WHO,
- refractory anaemia with excess of blast in transformation (RAEB T) according FAB,
- CMML (dysplastic type) according WHO,
or secondary acute myeloid leukaemia (sAML).
Blast count < 20 percent in bone marrow with or without chemotherapy at time of transplantation.
Patient eligible for standard and dose-reduced conditioning as per local guideline.
Patient age 18 - 60 years if donor is a HLA-matched unrelated donor (HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1) (one mismatch allowed):
Patient age 18 - 65 years if donor is a HLA-matched related donor ((HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1) (one anti¬gen-mismatch allowed):
No major organ dysfunction.
Written informed consent of the patient.

Exclusion criteria

Blasts > 20 % in bone marrow at time of transplantation
No written informed consent.
Central nervous involvement.
Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as
Total bilirubin, SGPT or SGOT > 2 times upper the normal level.
Left ventricular ejection fraction < 30 %.
Creatinine clearance < 30 ml/min.
DLCO < 35 % and/or receiving supplementary continuous oxygen.
Positive serology for HIV.
Pregnant or lactating women.
Patients with a life-expectancy of less than six months because of another debilitating disease.
Serious psychiatric or psychological disorders.
Invasive fungal infection at time of registration.